Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Abstract Background Neoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma.However, accurately predicting individual recurrence risk remains a significant challenge.We investigated circulating tumour DNA maison alhambra libbra (ctDNA) as a biomarker for recurrence in measurable stage IIIB/C melanoma p